These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38252655)

  • 21. Characterizing zero-dose and under-vaccinated children among refugees and internally displaced persons in the Democratic Republic of Congo.
    Nimpa MM; Cikomola Mwana-Wabene A; Otomba J; Mukendi JC; Danovaro-Holliday MC; Mboussou FF; Mwamba D; Kambala L; Ngwanga D; Mwanga C; Etapelong SG; Compaoré I; Yapi MD; Ishoso DK
    Trop Dis Travel Med Vaccines; 2024 Jul; 10(1):17. PubMed ID: 39004758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years.
    Yu XY; Chen ZP; Wang SY; Pan HR; Wang ZF; Zhang QF; Shen LZ; Zheng XP; Yan CF; Lu M; Chen B; Zheng Y; Zhang J; Lv HK; Huang SJ
    Vaccine; 2019 Jul; 37(32):4581-4586. PubMed ID: 31262585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).
    Wharton M; Strikas RA; Harpaz R; Rotz LD; Schwartz B; Casey CG; Pearson ML; Anderson LJ; ;
    MMWR Recomm Rep; 2003 Apr; 52(RR-7):1-16. PubMed ID: 12710832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Notes from the field: hepatitis E outbreak among refugees from South Sudan - Gambella, Ethiopia, April 2014-January 2015.
    Browne LB; Menkir Z; Kahi V; Maina G; Asnakew S; Tubman M; Elyas HZ; Nigatu A; Dak D; Maung UA; Nakao JH; Bilukha O; Shahpar C;
    MMWR Morb Mortal Wkly Rep; 2015 May; 64(19):537. PubMed ID: 25996097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of hepatitis E vaccination for pregnancy: a post-hoc analysis of a randomized, double-blind, controlled phase 3 clinical trial.
    Zhong G; Zhuang C; Hu X; Chen Q; Bi Z; Jia X; Peng S; Li Y; Huang Y; Zhang Q; Hong Y; Qiao Y; Su Y; Pan H; Wu T; Wei L; Huang S; Zhang J; Xia N
    Emerg Microbes Infect; 2023 Dec; 12(1):2185456. PubMed ID: 36877135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of concomitant administration of inactivated hepatitis A vaccine with other vaccines in children under 16 years old in post-marketing surveillance.
    Wu L; Yang S; Huang Z; Liu J; Guo X; Bai Q; Sun X
    Vaccine; 2023 Mar; 41(14):2412-2417. PubMed ID: 36872142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An evaluation of adverse events following an immunization campaign with the live, attenuated SA14-14-2 Japanese encephalitis vaccine in Cambodia.
    Hills SL; Soeung SC; Sarath S; Morn C; Dara C; Fischer M; Thigpen MC
    PLoS One; 2022; 17(6):e0269480. PubMed ID: 35679297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination coverage survey and seroprevalence among forcibly displaced Rohingya children, Cox's Bazar, Bangladesh, 2018: A cross-sectional study.
    Feldstein LR; Bennett SD; Estivariz CF; Cooley GM; Weil L; Billah MM; Uzzaman MS; Bohara R; Vandenent M; Adhikari JM; Leidman E; Hasan M; Akhtar S; Hasman A; Conklin L; Ehlman D; Alamgir A; Flora MS
    PLoS Med; 2020 Mar; 17(3):e1003071. PubMed ID: 32231368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.
    Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL
    Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High cholera vaccination coverage following emergency campaign in Haiti: Results from a cluster survey in three rural Communes in the South Department, 2017.
    Sharp A; Blake A; Backx J; Panunzi I; Barrais R; Nackers F; Luquero F; Deslouches YG; Cohuet S
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007967. PubMed ID: 32004316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006-2010.
    Naidu L; Chiu C; Habig A; Lowbridge C; Jayasinghe S; Wang H; McIntyre P; Menzies R
    Commun Dis Intell Q Rep; 2013 Dec; 37 Suppl():S1-95. PubMed ID: 24410428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial.
    Zhu FC; Zhang J; Zhang XF; Zhou C; Wang ZZ; Huang SJ; Wang H; Yang CL; Jiang HM; Cai JP; Wang YJ; Ai X; Hu YM; Tang Q; Yao X; Yan Q; Xian YL; Wu T; Li YM; Miao J; Ng MH; Shih JW; Xia NS
    Lancet; 2010 Sep; 376(9744):895-902. PubMed ID: 20728932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse events following immunisation (AEFI) of COVISHIELD vaccination among healthcare workers in Ghana.
    Marfoh K; Samba A; Okyere E; Acheampong F; Owusu E; Darko DNA; Zakariah J; Mensa H; Aidoo E; Mohammed Y
    BMJ Open; 2023 Jun; 13(6):e061643. PubMed ID: 37380201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral cholera vaccine coverage during a preventive door-to-door mass vaccination campaign in Nampula, Mozambique.
    Semá Baltazar C; Rafael F; Langa JPM; Chicumbe S; Cavailler P; Gessner BD; Pezzoli L; Barata A; Zaina D; Inguane DL; Mengel MA; Munier A
    PLoS One; 2018; 13(10):e0198592. PubMed ID: 30281604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parental perspectives of vaccine safety and experience of adverse events following immunisation.
    Parrella A; Gold M; Marshall H; Braunack-Mayer A; Baghurst P
    Vaccine; 2013 Apr; 31(16):2067-74. PubMed ID: 23422146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study.
    Mascolo A; di Mauro G; Fraenza F; Gaio M; Zinzi A; Pentella C; Rossi F; Capuano A; Sportiello L
    Front Immunol; 2022; 13():965171. PubMed ID: 36263025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Mobile Information Technology during Planning, Implementation and Evaluation of a Polio Campaign in South Sudan.
    Haskew J; Kenyi V; William J; Alum R; Puri A; Mostafa Y; Davis R
    PLoS One; 2015; 10(8):e0135362. PubMed ID: 26252383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility of a preventive mass vaccination campaign with two doses of oral cholera vaccine during a humanitarian emergency in South Sudan.
    Porta MI; Lenglet A; de Weerdt S; Crestani R; Sinke R; Frawley MJ; Van Herp M; Zachariah R
    Trans R Soc Trop Med Hyg; 2014 Dec; 108(12):810-5. PubMed ID: 25311798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Tran VN; Nguyen HA; Le TTA; Truong TT; Nguyen PT; Nguyen TTH
    Vaccine; 2021 Oct; 39(44):6485-6491. PubMed ID: 34607748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An innovative approach in monitoring oral cholera vaccination campaign: integration of a between-round survey.
    Ateudjieu J; Yakum MN; Goura AP; Tembei Ayok M; Guenou E; Kangmo Sielinou CB; Kiadjieu FF; Tsafack M; Douanla Koutio IM; Tchio-Nighie KH; Tchokomeni H; Ntsekendio PN; Sack DA
    BMC Public Health; 2022 Feb; 22(1):238. PubMed ID: 35123444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.